

# Specimens:			Depot:
Collect Date:	Time:	Ву:	ABN Signed:
MR #:		A #:	

REQUIRED (PRINT OR F	ATIENT LABEL)			La amble A1			
Name(Last, First, MI)	·			_ <b>[Address]</b> SEE ATTACHED			
Date of Birth	Sex:(circle) M F			- REQ			
Street Address		Phone:	Fax:				
Street Address 2							
City, State, Zip		(Doctor):		-			
Phone Number	Chart Number						
Indicate primary (1) and secondary	(2) insurance						
Blue Choice/Shield Child H	ealth Plus MVP						
Blue Choice Medical	<del></del>						
		Phone Results to:	Fax Results	to:			
Blue Choice Medicare Medicar	re Aetna	Ordering Provider's Signature	Da	ate of Signature			
Other:							
1. Subscriber ID:		Diagnosis Mandatory: Signs/Symptoms or ICD10 Codes If ordered for screening, list test name here and write "SCREENING" after it					
Subscriber's Name:							
Relationship to Subscriber:		Send Additional Reports To: (Fu	ull Name/Address)				
2. Secondary Subscriber ID:		·					
Subscriber's Name:		Compliance is Mandatory and Regulated. For the laboratory to bill properly and receive payment for tests ordered on Medicare Beneficiaries, specific ICD-10 code(s) or a descriptive diagnosis must be included on each patient for each test ordered. It is critical that the diagnosis provided to the lab is consistent with those recorded in the patient					
Relationship to Subscriber:		each test ordered.It is critical that th medical record on the date of service	ne diagnosis provided to the lab is one.	consistent with those recorded in the patient			
Patient's weightlbs ORkgs  Due date (EDC) Determined by:							
CRL (mm): NT (mr	n): Twin B	CRL (mm):	Twin B NT (mm):				
Number of fetuses?  ADDITIONAL INFORMATION:							
Singleton Twins Ur	nknown For twins, is pre	egnancy monochorionic?	lo ☐ Yes ☐ Unknov	vn			
Patient's race?							
☐ Non-Black ☐ Black ☐ Uı	nknown						
Was the patient diabetic at the time of c	onception?	s this an in vitro fertilization pre	egnancy?				
□ No □ Yes		□ No □ Yes	Unknown				
		Has the patient had a previous r		in programay?			
Does the patient currently smoke cigare	ntesr			s pregnancy:			
☐ No ☐ Yes	I	☐ No ☐ Yes	Unknown				
Has the patient taken valproic acid or ca		cy?					
No Yes; specify medication:							
Has the patient had a previous pregnancy with trisomy? (i.e., Down syndrome, trisomy 18 or 13)							
□ No □ Yes; specify abnormality:							
Is there a family history of neural tube defects? (i.e., spina bifida, anencephaly, encephalocele)							
☐ No ☐ Yes; specify the relationship of the affected individual to the fetus:							
SELECT THE TEST YOU INTEND TO O	RDER:						
MSSQA 3000143 Maternal Se			Perform blood draws when	CRL is within the appropriate range:			
MSSAF 3000144 Maternal Se			First Trimest	ter: CRL 43   83.9mm			
MSSFT 3000144 Maternal Serum Screen First Trimester							
<del>-</del>							
PATIENT CONSENT							
I have read the information on the back of this form and discussed it with my health care provider. My questions about Prenatal Screening have been answered. I am aware that this testing is widely accepted as a screening test for birth defects, but that it may not yet be endorsed by New York State. I authorize withdrawal and analysis of the necessary blood sample. I also							

I have read the information on the back of this form and discussed it with my health care provider. My questions about Prenatal Screening have been answered. I am aware that this testing is widely accepted as a screening test for birth defects, but that it may not yet be endorsed by New York State. I authorize withdrawal and analysis of the necessary blood sample. I also authorize the UR Medicine Clinical Laboratories and the Rochester Regional Genetics Program to release my test results to my health care provider. I authorize follow up information about this pregnancy, as required by New York State, to be released confidentially to the Rochester Regional Genetics program. I agree that the serum which remains after results are completed may be used anonymously to develop techniques for prenatal diagnosis.

Patient/Legal Guardian: Date: \_\_\_\_/\_\_\_ Health Care Provider:

## Prenatal Screening Information for Consent

- 1. 1ST TRIMESTER SCREENING (Must be done between 11 to 13 6/7 weeks of pregnancy)
- \*\*\* Tells how high the chance is that the baby has Down syndrome or Trisomy 18\*\*\*

1st Trimester Screening combines an ultrasound to measure the thickness of skin at the back of the baby's neck (the Nuchal Translucency or "NT") with a blood test to measure two substances (hCG and PAPP-A) normally found in the pregnant woman's blood. It is normal for the NT measurement to vary among healthy fetuses, and for the hCG and PAPP-A levels to vary in normal pregnancies. But if the NT measures larger than average, or the hCG or PAPP-A are high or low, the risk for chromosome problems like Down syndrome may be increased. If 1st Trimester Screening shows a high enough risk, the woman can choose an additional test like amniocentesis or chorionic villus sampling (CVS) to tell for sure if the baby is healthy. In some cases, 1st Trimester Screening may indicate that the baby's chance for a chromosome problem is low enough that a woman who was planning to have amniocentesis or CVS might choose not to have it. 1st Trimester Screening screens for:

<u>Down Syndrome</u> - Down syndrome is caused by an extra 21st chromosome. It results in moderate mental retardation, some physical differences and sometimes health problems such as heart defects. Children with Down syndrome have special education needs, but often these are arranged through their regular school.

<u>Trisomy 18</u> - Trisomy 18 is caused by an extra 18th chromosome. It is a very severe birth defect causing many health problems and severe mental retardation. Nine out of ten babies born with Trisomy 18 do not survive beyond one year of life.

1st Trimester Screening identifies about 85% of pregnancies where the baby has Down syndrome or Trisomy 18, however in about 15% of pregnancies with these conditions, the screening result is normal. 1st Trimester Screening does not screen for Neural Tube Defects or other open fetal defects. An AFP ONLY test can be done after 14 weeks of pregnancy to screen for these.

2. 2nd TRIMESTER AFP+ SCREENING (Also called the "Quad Screen" - Must be drawn after 14 and 24 6/7 weeks of pregnancy) The recommended time for maternal serum screening is 16 to 18 weeks of pregnancy.

\*\*\*Tells how high the chance is for Down syndrome, Trisomy 18, or Spina bifida and other open fetal defects\*\*\*

AFP+ Screening is a blood test that measures the levels of four substances (AFP, Unconjugated Estriol, hCG, and Inhibin-A) in a pregnant woman's blood. It is normal for the levels of these to vary among different women, but women with particularly high or low values may be at increased risk to have a baby with certain birth defects. AFP+ Screening is usually done between 15-18 weeks of pregnancy. The AFP+ Quad Screen test screens for:

<u>Down Syndrome</u> - Down syndrome is caused by an extra 21st chromosome. It results in moderate mental retardation, some physical differences and sometimes health problems such as heart defects. Children with Down syndrome have special education needs, but often these are arranged through their regular school.

**Trisomy 18** - Trisomy 18 is caused by an extra 18th chromosome. It is a very severe birth defect causing many health problems and severe mental retardation. Nine out of ten babies born with Trisomy 18 do not survive beyond one year of life.

<u>Neural Tube Defects</u> (spina bifida and anencephaly)- Neural tube defects are birth defects where the brain (anencephaly) or part of the spinal cord (spina bifida) does not form normally and may not be covered with skin or bone. Babies with anencephaly are usually stillborn or die shortly after birth. Babies with spina bifida usually have medical problems including leg paralysis, impaired bowel and bladder control, "water on the brain", and sometimes learning problems.

Abdominal Wall Defects- These birth defects are caused by an opening in the layer of muscle and skin near the "belly button". Although serious, they can often be corrected with surgery.

AFP+ Screening identifies about 75-80% of pregnancies where the baby has Down syndrome, and about 60% of pregnancies with Trisomy 18. About 90% of pregnancies with spina bifida or other open fetal defects are identified by AFP+ Screening.

3. 2nd TRIMESTER AFP ONLY SCREENING (Must be done after 14 and 24 6/7 weeks of pregnancy)

\*\*\*Tells how high the chance is for Spina bifida and other open fetal defects. Does NOT screen for Down syndrome or Trisomy 18\*\*\*

AFP ONLY Screening is a blood test that measures the level of AFP in a woman's blood. It should be ordered only in cases where a woman has already had 1st Trimester screening or CVS, or if it is recommended after a Quad screen has shown a mild AFP elevation.

## What are "Screening" Tests?

1st Trimester Screening, AFP+ Screening, and AFP ONLY are "screening" tests because they cannot tell for sure whether the fetus does or does not have a birth defect. But they can tell if there is a greater than average risk that the baby has certain birth defects. Further testing (like ultrasound or amniocentesis) can be done to tell with greater certainty if a birth defect is or is not present. About 7% of women who have a screening test will be offered further testing, and most of the time these follow up tests will show that the baby is healthy.